SCHEMBL2682508

SCHEMBL2682508

O=C(O)Cc1cc(C(=O)c2ccc3cc(-c4ccccc4)[nH]c3c2)sc1Br

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 1/20 0.54
SENP8 Q96LD8 1/20 0.54
SENP7 Q9BQF6 1/20 0.54
SENP6 Q9GZR1 1/20 0.54
PPARG P37231 1/20 0.46
CHEK2 O96017 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 1/20 0.38
CYP19A1 P11511 1/20 0.37
ITK Q08881 7/20 0.36
ESR1 P03372 1/20 0.36
F2 P00734 1/20 0.36
F7 P08709 1/20 0.36
F3 P13726 1/20 0.36
FFAR1 O14842 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3056696 0.88 CASP3 (0.55) CASP3SENP8SENP7SENP6PPARG
SCHEMBL2683121 0.87 CASP3 (0.47) CASP3SENP8SENP7SENP6PPARG
SCHEMBL3058848 0.81 CASP3 (0.51) CASP3SENP8SENP7SENP6PPARG
SCHEMBL3047750 0.79 CASP3 (0.52) CASP3SENP8SENP7SENP6CHEK2
SCHEMBL5026628 0.79 CASP3 (0.52) CASP3SENP8SENP7SENP6CHEK2
SCHEMBL3704691 0.72 CASP3 (1.00) CASP3SENP8SENP7SENP6PPARG
SCHEMBL29941485 0.72 CASP3 (1.00) CASP3SENP8SENP7SENP6PPARG
SCHEMBL5443742 0.70 CASP3 (0.77) CASP3SENP8SENP7SENP6PPARG
SCHEMBL30344399 0.70 CASP3 (0.77) CASP3SENP8SENP7SENP6PPARG
SCHEMBL16904651 0.69 MAPT (0.68) NPC1RAB9AMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404728-B2 Small-molecule botulinum toxin inhibitors MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2013-03-26 US disclosed
US-20120114696-A1 SMALL-MOLECULE BOTULINUM TOXIN INHIBITORS US ARMY, SECRETARY OF THE ARMY 2012-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120114696-A1 SMALL-MOLECULE BOTULINUM TOXIN INHIBITORS BTD, BCHE, ACHE CASP3 2001/4885SENP8 1042/4885SENP7 1546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.